{"id":12940,"date":"2024-04-17T16:36:52","date_gmt":"2024-04-17T16:36:52","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/non-classifiee\/ongoing-clinical-trial-a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer-azur-1-copy\/"},"modified":"2024-04-17T16:54:26","modified_gmt":"2024-04-17T16:54:26","slug":"ongoing-clinical-trial-a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer-azur-1-copy","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/ongoing-clinical-trial-a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer-azur-1-copy\/","title":{"rendered":"Essai clinique en cours : \u00e9tude de phase 3 du dostarlimab p\u00e9riop\u00e9ratoire chez des participants atteints d’un cancer du c\u00f4lon r\u00e9s\u00e9cable T4N0 ou de stade III dMMR\/MSI-H non trait\u00e9 (AZUR-2)"},"content":{"rendered":"

Avril 2024\u00a0\u00a0<\/strong><\/p>\n

Cette \u00e9tude vise \u00e0 \u00e9valuer l’efficacit\u00e9 du traitement par dostarlimab administr\u00e9 avant et apr\u00e8s la chirurgie (p\u00e9riop\u00e9ratoire) par rapport \u00e0 la norme de soins chez les participants atteints d’un cancer du c\u00f4lon T4N0 ou de stade III avec d\u00e9faut de r\u00e9paration des m\u00e9sappariements (dMMR) \/ instabilit\u00e9 des microsatellites \u00e9lev\u00e9e (MSI-H) sans traitement ou chirurgie pr\u00e9alable. Pour en savoir plus sur les biomarqueurs, cliquez ici<\/a>.\u00a0\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n\n\n\n\n\n\n
Stade 1<\/span><\/b>\u00a0<\/span><\/td>\nStade 2<\/span><\/b>\u00a0<\/span><\/td>\nStade 3<\/span><\/b>\u00a0<\/span><\/td>\nStade 4<\/span><\/b>\u00a0<\/span><\/td>\n<\/tr>\n
T1 or T2<\/span>\u00a0<\/span><\/td>\nT3 or T4<\/span>\u00a0<\/span><\/td>\nAny T<\/span>\u00a0<\/span><\/td>\nAny T<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
N0<\/span>\u00a0<\/span><\/td>\nN0<\/span>\u00a0<\/span><\/td>\nN1 or N2<\/span>\u00a0<\/span><\/td>\nAny N<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
M0<\/span>\u00a0<\/span><\/td>\nM0<\/span>\u00a0<\/span><\/td>\nM0<\/span>\u00a0<\/span><\/td>\nM1<\/span>\u00a0<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

T1. Le cancer s’est d\u00e9velopp\u00e9 \u00e0 travers les premi\u00e8res couches du c\u00f4lon ou du rectum.\u00a0<\/span>\u00a0<\/span><\/p>\n

T2. Le cancer a progress\u00e9 dans l’\u00e9paisse couche musculaire du c\u00f4lon ou du rectum.\u00a0<\/span>\u00a0<\/span><\/p>\n

T3. Le cancer a travers\u00e9 toute la paroi du c\u00f4lon ou du rectum.\u00a0<\/span>\u00a0<\/span><\/p>\n

T4. Le cancer a franchi toute la paroi du c\u00f4lon ou du rectum et touch\u00e9 les tissus ou les organes avoisinant.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n

N0. Il n’y a pas de propagation aux ganglions lymphatiques\u00a0<\/span>\u00a0<\/span><\/p>\n

N1. Le cancer est pr\u00e9sent dans 1 \u00e0 3 ganglions lymphatiques\u00a0<\/span>\u00a0<\/span><\/p>\n

N2. Le cancer est pr\u00e9sent dans quatre ganglions lymphatiques ou plus.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0M0. Le cancer ne s’est pas propag\u00e9 \u00e0 un ou plusieurs organes distants.\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0M1. Le cancer s’est propag\u00e9 \u00e0 un ou plusieurs organes distants.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Le dostarlimab est un inhibiteur de point de contr\u00f4le immunitaire (un type d’immunoth\u00e9rapie) qui est utilis\u00e9 pour traiter les cancers, y compris le cancer colorectal. Dans une \u00e9tude portant sur 14 patients atteints d’un cancer rectal \u00e0 un stade pr\u00e9coce, le traitement par le dostarlimab avant l’intervention chirurgicale a entra\u00een\u00e9 une r\u00e9ponse clinique compl\u00e8te remarquable chez 100 % des patients.\u202f\u202fLes donn\u00e9es concernant les tumeurs qui expriment le dMMR\/MSI-H sugg\u00e8rent qu’une approche p\u00e9riop\u00e9ratoire avec un agent d’immunoth\u00e9rapie tel que le dostarlimab peut d’autant plus am\u00e9liorer les r\u00e9sultats en termes de survie<\/span>1<\/span>.\u00a0 Pour plus d’informations sur cet essai clinique : <\/span>https:\/\/clinicaltrials.gov\/study\/NCT05855200<\/span><\/a>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Il existe actuellement quatre sites d’essais cliniques au Canada pour l’AZUR-2 :\u00a0<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>

Halifax, Nouvelle-\u00c9cosse\u00a0\u00a0<\/strong><\/p>\n

Site de recherche de GSK\u00a0<\/span>\u00a0<\/span><\/p>\n

Contact:\u202fGSKClinicalSupportHD@gsk.com<\/a><\/span><\/p>\n

Chercheur principal : Katerina Neumann\u00a0<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div>

\n
\n
\n
\n
\n

Recrutement<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

Edmonton, Alberta<\/strong>\u00a0<\/span>\u00a0<\/span><\/p>\n

Site de recherche de GSK\u00a0<\/span>\u00a0<\/span><\/p>\n

Contact:\u202fGSKClinicalSupportHD@gsk.com <\/a><\/span>\u00a0<\/span><\/p>\n

Chercheur principal : Jennifer Spratlin\u00a0<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div>

\n
\n
\n
\n
\n

Recrutement<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

Ottawa, Ontario\u00a0\u00a0<\/strong><\/p>\n

Site de recherche de GSK\u00a0<\/span>\u00a0<\/span><\/p>\n

Contact:\u202fGSKClinicalSupportHD@gsk.com <\/a><\/span>\u00a0<\/span><\/p>\n

Chercheur principal : Rebecca Auer<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div>

\n
\n
\n
\n
\n

Recrutement<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

Toronto, Ontario\u00a0<\/strong>\u00a0<\/span><\/p>\n

Site de recherche de GSK\u00a0<\/span>\u00a0<\/span><\/p>\n

Contact:\u202fGSKClinicalSupportHD@gsk.com <\/a><\/span>\u00a0<\/span><\/p>\n

Chercheur principal : Eric Chen\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div>

\n
\n
\n
\n
\n

Recrutement<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>

Montr\u00e9al, Qu\u00e9bec \u00a0<\/strong><\/p>\n

Site de recherche de GSK\u00a0<\/span>\u00a0<\/span><\/p>\n

Contact:\u202fGSKClinicalSupportHD@gsk.com <\/a><\/span>\u00a0<\/span><\/p>\n

Chercheur principal : Jamil Asselaah\u00a0<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n

Si vous r\u00e9sidez au Qu\u00e9bec, vous pouvez obtenir de l’aide en mati\u00e8re de navigation des essais cliniques en communiquant avec :\u00a0<\/span>\u00a0<\/span><\/p>\n

OncoQu\u00e9bec : <\/span>info@oncoquebec.com<\/span><\/a>\u00a0<\/span><\/p>\n

et\/ou\u00a0\u00a0<\/span>\u00a0<\/span><\/p>\n

Recherche Clinique Qu\u00e9bec : <\/span>info@recherchecliniquequebec.com<\/span><\/a>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div><\/div><\/div>

\n
\n
\n
\n
\n

Recrutement<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"

This study aims to investigate dostarlimab therapy in patients with locally advanced mismatch-repair deficient (dMMR) \/ microsatellite instability high (MSI-H) rectal cancer who have not received any previous treatment. Patients who achieve a complete clinical response (no detectable tumour remains)…<\/p>\n","protected":false},"author":5,"featured_media":10938,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42,57,98],"tags":[],"class_list":["post-12940","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue","category-essais-cliniques","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/12940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=12940"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/12940\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/10938"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=12940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=12940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=12940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}